Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ONCY
ONCY logo

ONCY Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Oncolytics Biotech Inc (ONCY) Today? Analysis, Price Targets, and 2026 Outlook.

No data

No data

No data

No data

Growth

Profitability

Efficiency

Wall Street analysts forecast ONCY stock price to rise
6 Analyst Rating
Wall Street analysts forecast ONCY stock price to rise
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.935
sliders
Low
3
Averages
5.5
High
10
Current: 0.935
sliders
Low
3
Averages
5.5
High
10
Lake Street
Chad Messer
Buy
downgrade
$7 -> $5
AI Analysis
2026-04-07
Reason
Lake Street
Chad Messer
Price Target
$7 -> $5
AI Analysis
2026-04-07
downgrade
Buy
Reason
Lake Street analyst Chad Messer lowered the firm's price target on Oncolytics to $5 from $7 and keeps a Buy rating on the shares after the company reported FY25 results and announced it has scheduled a Type C meeting with the FDA for April 16 to align on the design of a single-arm pivotal study for pelareorep in squamous cell anal carcinoma.
H.C. Wainwright
H.C. Wainwright
upgrade
$5 -> $10
2025-11-17
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$5 -> $10
2025-11-17
upgrade
Reason
H.C. Wainwright raised the firm's price target on Oncolytics to $10 from $5 and keeps a Buy rating on the shares. The firm says the company's "compelling" data in gastrointestinal tumors increase its confidence ahead of the FDA meeting. H.C. Wainwright is increasingly confident that pelareorep is advancing toward "actionable regulatory pathways" across three "high-value" cancer indications.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ONCY
Unlock Now

People Also Watch